Characteristics and Adverse Events of Patients for Whom Nifurtimox Was Released Through CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease — United States, 2001–2021 - KIVIRID

Characteristics and Adverse Events of Patients for Whom Nifurtimox Was Released Through CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease — United States, 2001–2021

Authors: Andrew Abbott, Susan P. Montgomery, Rebecca J. Chancey

Published: 2022-03-10

DOI: 10.15585/mmwr.mm7110a2

Source: Full article

Abstract

No abstract found.